恶性胶质瘤抗血管生成治疗药物的研究进展  

Advances in anti-angiogenic therapeutic drugs for malignant glioma

作　　者：王斌[1,2,3] 司同国 WANG Bin;SI Tongguo(Department of Interventional Radiology,Tianjin Huanhu Hospital;Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases,Tianjin 300350,China)

机构地区：[1]天津市环湖医院肿瘤介入科 [2]天津市脑血管与神经变性重点实验室,天津300350 [3]天津医科大学附属肿瘤医院介入治疗科,天津300060

出　　处：《岭南现代临床外科》2019年第5期632-636,641,共6页Lingnan Modern Clinics in Surgery

摘　　要：恶性神经胶质瘤是成人中最常见和最具侵袭性的原发性脑肿瘤,其显著的神经系统症状和无法治愈的特性给患者及其家庭带来了巨大的痛苦和严重的医疗负担。由于当前标准治疗方案难以达到理想效果,患者中位数生存期不足15个月。血管生成是恶性胶质瘤的标志,现已成为重要的治疗新靶标。本文回顾了抗血管治疗的作用机制和抗血管药物在恶性胶质瘤治疗的临床应用探索,并简要讨论了恶性胶质瘤抗血管生成治疗药物的研究进展。Malignant glioma is the most common and invasive primary brain tumor in adults,and its significant neurological and incurable properties bring great pain and serious medical burden to patients and their families. The median survival of patients is less than 15 months due to the current standard treatment regimen that is difficult to achieve. Angiogenesis is a hallmark of malignant glioma and has become an important new therapeutic target. This article reviews the mechanism of anti-angiopathy and the clinical application of anti-angiogenic drugs in the treatment of malignant glioma,and briefly discusses the research progress of anti-angiogenic drugs for malignant glioma.

关 键 词：恶性胶质瘤 抗血管治疗药物 作用机制 研究进展 

分 类 号：R739.41[医药卫生—肿瘤]